Digestive Diseases and Sciences

, Volume 56, Issue 1, pp 203–207 | Cite as

Effectiveness of the Immunofecal Occult Blood Test for Colorectal Cancer Screening in a Large Population

  • Haiyun Yang
  • Zhizheng Ge
  • Jun Dai
  • Xiaobo Li
  • Yunjie Gao
Original Article



Guaiac tests are the most widely used tests to detect colorectal cancer (CRC). However, their sensitivity is relatively low and results may be affected by various factors. Immunofecal occult blood test (IFOBT) is specific for human hemoglobin and does not require dietary restrictions.


The aim of this study was to evaluate the effectiveness of IFOBT for the screening of precancerous lesions and CRC.


From July 2006 to June 2007, IFOBT was performed on 5,919 adults who received periodic health examinations in our hospital. The positive cases were examined by colonoscopy and a double-contrast barium enema. Diagnosis was confirmed by histopathological analysis.


Positive IFOBT was detected in 314 of 5,919 cases (5.30%). Further examinations were made in 264 IFOBT-positive cases. Of these, 116 cases with colorectal cancer (16 cases) or precancerous lesions (94 cases with colorectal adenomatous polyps and 6 cases with active ulcerative colitis) were detected. The total detection rate of CRC and precancerous lesions was 43.94% (116/264). TNM classification of 16 CRC cases was as follows: TNM I in eight cases (50.00%), TNM II in seven cases (43.75%) and TNM III in one case (6.25%), indicating IFOBT can detect CRC in the early stages.


Regular IFOBT can detect precancerous lesions and CRC in early stages and can thus reduce mortality from CRC.


Immunofecal occult blood test Lower gastrointestinal bleeding Colorectal cancer Screen 


Financial support

Supported by a grant from the Shanghai Leading Academic Discipline Project (No. Y0205 to Zhi-Zheng Ge).

Competing interests

The authors declare that they have no competing interests.


  1. 1.
    Daniel L, Joseph J, Robert H, et al. Noninvasive testing for colorectal cancer: a review. Am J Gastroenterol. 2005;100:1393–1403.CrossRefGoogle Scholar
  2. 2.
    Autier P. Should organised faecal occult blood test screening be established? Ann Oncol. 2002;13(1):57–60.CrossRefPubMedGoogle Scholar
  3. 3.
    Strul H, Arber N. Fecal occult blood test for colorectal cancer screening. Ann Oncol. 2002;13(1):51–56.CrossRefPubMedGoogle Scholar
  4. 4.
    Bleiberg H. Hemoccult should no longer be used for the screening of colorectal cancer. Ann Oncol. 2002;13(1):44–46.CrossRefPubMedGoogle Scholar
  5. 5.
    Levi Z, Hazazi R, Rozen P, et al. A quantitative immunochemical faecal occult blood test is more efficient for detecting significant colorectal neoplasia than a sensitive guaiac test. Aliment Pharmacol Ther. 2006;23(9):1359–1364.CrossRefPubMedGoogle Scholar
  6. 6.
    Nakama H, Kamijo N. Accuracy of immunological fecal occult blood testing for colorectal cancer screening. Prev Med. 1994;23(3):309–313.CrossRefPubMedGoogle Scholar
  7. 7.
    Rozen P. Cancer of the gastrointestinal tract: early detection or early prevention? Eur J Cancer Prev. 2004;13(1):71–75.CrossRefPubMedGoogle Scholar
  8. 8.
    Levin B, Brooks D, Smith RA, et al. Emerging technologies in screening for colorectal cancer: CT colonography, immunochemical fecal occult blood tests, and stool screening using molecular markers. CA Cancer J Clin. 2003;53(1):44–55.CrossRefPubMedGoogle Scholar
  9. 9.
    Labianca R, Beretta GD, Mosconi S, et al. Colorectal cancer: screening. Ann Oncol. 2005;16(Suppl 2: ii):127–132.Google Scholar
  10. 10.
    Atkin WS, Northover JM. Protagonist: population based endoscopic screening for colorectal cancer. Gut. 2003;52(3):323–326.CrossRefGoogle Scholar
  11. 11.
    Brenner DE, Rennert G. Fecal DNA biomarkers for the detection of colorectal neoplasia: attractive, but is it feasible? J Natl Cancer Inst. 2005;97(15):1107–1109.CrossRefPubMedGoogle Scholar
  12. 12.
    Mandel JS, Bond JH, Church TR. Reducing mortality from colorectal cancer by screening for faecal occult blood. Minnesota colon cancer control study. N Eng J Med. 1993;328:1365–1371.CrossRefGoogle Scholar
  13. 13.
    Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal—occult-blood screening for colorectal cancer. Lancet. 1996;348:1472–1477.CrossRefPubMedGoogle Scholar
  14. 14.
    Kronborg O, Fenger C, Olsen J, et al. Randomised study of screening for colon cancer with faecal-occult-blood test. Lancet. 1996;348:1467–1471.CrossRefPubMedGoogle Scholar
  15. 15.
    La Vecchia C. Fecal occult blood screening for colorectal cancer: open issues. Ann Oncol. 2002;13(1):31–34.CrossRefPubMedGoogle Scholar
  16. 16.
    Yan HY, Ge ZZ. Research status of fecal occult blood test in the early diagnosis of colorectal cancer. Chin J Gastroenterol. 2006;11(6):376–378.Google Scholar
  17. 17.
    Anderson WF, Guyton KZ, Hiatt RA, et al. Colorectal cancer screening for persons at average risk. J Natl Cancer Inst. 2002;94(15):1126–1133.PubMedGoogle Scholar
  18. 18.
    Vernon SW. Participation in colorectal cancer screening: a review. J Natl Cancer Inst. 1997;89(19):1406–1422.CrossRefPubMedGoogle Scholar
  19. 19.
    Yeazel MW, Church TR, Jones RM, et al. Colorectal cancer screening adherence in a general population. Cancer Epidemiol Biomarkers Prev. 2004;13(4):654–657. (Erratum in: Cancer Epidemiol Biomarkers Prev. 2004;13(9):1550).PubMedGoogle Scholar
  20. 20.
    Scales CD Jr, Fein S, Muir AJ, et al. Clinical utilization of digital rectal examination and fecal occult blood testing upon hospital admission. J Clin Gastroenterol. 2006;40(10):913–918.CrossRefPubMedGoogle Scholar
  21. 21.
    Atkin WS, Morson BC, Cuzick J. Long-term risk of colorectal cancer after excision of rectosigmoid adenomas. N Engl J Med. 1992;326:658–662.CrossRefPubMedGoogle Scholar
  22. 22.
    Rex DK, Overhiser AJ, Chen SC. Estimation of impact of American college of radiology recommendations on CT clonograph reporting for resection of high-risk adenoma findings. Am J Gastroenterol. 2009;104:149–153.CrossRefPubMedGoogle Scholar
  23. 23.
    Crespi M, Lisi D. Is colorectal cancer screening by fecal occult blood feasible? Ann Oncol. 2002;13(1):47–50.CrossRefPubMedGoogle Scholar
  24. 24.
    Mizutani S, Fumitani M, Kaneshiro E, et al. Fundamental evaluation of fully automated fecal occult blood analyzer “OC-SENSORμ”. J Med Pharm Sci. 2002;47(5):769–773.Google Scholar
  25. 25.
    Noboru G, Michiko F, Keiko I, et al. Basic study of OC-SENSOR μ, a compact fully automated immunochemistry analyzer for fecal occult blood tests. J Clin Lab Inst Reag. 2002;25(1):57–62.Google Scholar
  26. 26.
    Vilkin A, Rozen P, Levi Z, et al. Performance characteristics and evaluation of an automated-developed and quantitative, immunochemical, fecal occult blood-screening test. Am J Gastroenterol. 2005;100(11):2519–2525.CrossRefPubMedGoogle Scholar
  27. 27.
    Castiglione G, Grazzini G, Miccinesi G, et al. Basic variables at different positivity thresholds of a quantitative immunochemical test for faecal occult blood. J Med Screen. 2002;9(3):99–103.CrossRefPubMedGoogle Scholar
  28. 28.
    Robert A, Vilma C, Harmon J. American cancer society guidelines for the early detection of cancer. CA Cancer J Clin. 2006;56:11–25.CrossRefGoogle Scholar
  29. 29.
    Smith RA, Cokkinides V, Eyre HJ. American cancer society guidelines for the early detection of cancer, 2006. CA Cancer J Clin. 2006;56(1):11–25 (quiz 49–50).CrossRefPubMedGoogle Scholar
  30. 30.
    U.S. Preventive Services Task Force. Screening for colorectal cancer: recommendation and rationale. Am Fam Physician. 2002;66(12):2287–2290.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Haiyun Yang
    • 1
  • Zhizheng Ge
    • 1
  • Jun Dai
    • 1
  • Xiaobo Li
    • 1
  • Yunjie Gao
    • 1
  1. 1.Department of Gastroenterology, Renji Hospital, Shanghai Institute of Digestive DiseaseShanghai Jiao Tong University School of MedicineShanghaiChina

Personalised recommendations